Ecron Acunova Limited - pharma in Bangalore, Karnataka, India. FY 2026 financials & compliance.
CIN U73100KA2004PLC035260 Incorporated 17 December 2004 ROC Bangalore HQ Bangalore, Karnataka, India
Active Public Limited Company pharma
Revenue · FY 2025
₹75.29 Cr
▲ 20% YoY
Net profit · FY 2025
₹16.19 Cr
Net margin 21.5%
EBITDA · FY 2025
₹11.04 Cr
EBITDA margin 14.7%
Authorised capital
₹45 Cr
Registered with MCA
Paid-up capital
₹42.98 Cr
Issued & subscribed
Open charges
₹102.69 Cr
Satisfied ₹147.21 Cr
Company age
22 yrs
Est. 2004
Employees · EPFO
123
Provident fund records

About Ecron Acunova Limited

Data last updated:

Ecron Acunova Limited is a public limited company based in Bangalore, Karnataka, India, a subsidiary of Take Solutions Limited. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 17 December 2004 and has been in existence for over 22 years.

The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U73100KA2004PLC035260. Its GSTIN is 29AAECM1039J2ZD (Karnataka). The company holds 3 GST registrations, of which 2 are active.

The company has an authorised share capital of ₹45 Cr and a paid-up capital of ₹42.98 Cr. It was formerly known as Molecular Cellular Research Pvt Ltd and Manipal Acunova Limited. It is led by directors including Ranganathan Praveen and Priya Jebarani Aldam.

Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Mobius Towers Sjr – I Park Epip Whitefield, Bangalore, Karnataka, India – 560066.

As per the financials filed for FY 2025, the company reported a revenue of ₹75.29 Cr, a growth of 20% compared to the previous year. For the same year it recorded a net profit of ₹16.19 Cr (net margin 21.5%) and EBITDA of ₹11.04 Cr (EBITDA margin 14.7%). Revenue has declined at a compounded annual rate (CAGR) of 6% over three years and 8% over five years.

The company has about 123 employees on its provident fund (EPFO) records.

The company is associated with 2 brands: Ecron and Navitas Life Sciences. As per MCA filings, the company has open charges of ₹102.69 Cr and satisfied charges of ₹147.21 Cr on record. Court records list 9 cases involving the company, including 3 filed by the company and 6 filed against it; 3 cases are pending. The company has 22 deals on record (12 funding rounds, 10 secondary share transfers), with disclosed funding of ₹79.04 Cr; the latest was in August 2016. Its 3 peer companies in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development) are compared by revenue, 2 larger and 1 smaller; the largest is QPS Bioserve India Private Limited with revenue of ₹78.02 Cr. The company has 9 MSME Form 1 returns on record between 2019 and 2023, listing 665 overdue payments to 31 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website navitaslifesciences.com.

Company details

CIN U73100KA2004PLC035260
Registration Number 035260
Incorporation Date 17 December 2004
ROC Bangalore
Listing Status Unlisted
Company Status Active
Parent Company Take Solutions Limited
Compliance Status Active Compliant

Name history

Ecron Acunova has undergone 3 name changes throughout its history. The company was previously known as Molecular Cellular Research Pvt Ltd, Manipal Acunova Limited, and Manipal Acunova Private Limited. The current legal name is Ecron Acunova Limited.

Company NameStatus
Ecron Acunova LimitedCurrent
Molecular Cellular Research Pvt LtdPrevious
Manipal Acunova LimitedPrevious
Manipal Acunova Private LimitedPrevious

Contact details

Ecron Acunova Limited's registered office is in Bangalore, Karnataka. Its website is navitaslifesciences.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Social Media
  • Registered Address
    Mobius Towers Sjr – I Park Epip Whitefield, Bangalore, Karnataka, India – 560066
  • Industry
    Pharma, Pharma Contract R&D

To see the full contact details of Ecron Acunova Limited, buy the company report.

Comprehensive company report
Ecron Acunova Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Ecron Acunova operates two associated brands: Ecron and Navitas Life Sciences. Each brand links to its own profile.

BrandDescriptionWebsite
Develops and manages solar energy projects, from design and installation to operations.ecron.in
Clinical, regulatory, safety and compliance services for clinical developmentnavitaslifesciences.com

Business activity

The main business activity of Ecron Acunova is professional, scientific and technical. In detail, this covers scientific research and development.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
MProfessional, Scientific and TechnicalM5Scientific research and development

To see the full business activity and turnover split of Ecron Acunova Limited, buy the company report.

Financials of Ecron Acunova Limited

FY 2025 filings available

Ecron Acunova Limited reported revenue of ₹75.29 Cr (up 20% YoY) for FY 2025.

Revenue · FY 2025
₹75.29 Cr ▲ 20%
Net profit · FY 2025
₹16.19 Cr margin 21.5%
EBITDA · FY 2025
₹11.04 Cr margin 14.7%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▲ 20%
3 years · compounded
▼ 6%
5 years · compounded
▼ 8%
EBITDA CAGR growth
1 year
▲ 19%
3 years · compounded
▲ 7%
5 years · compounded
▼ 9%

Revenue rose 20% in the latest year, though over five years it has declined at a compounded annual rate (CAGR) of 8%. EBITDA rose 19% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue₹75.29 Cr
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹11.04 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹16.19 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin14.7%
Net Profit Margin21.5%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Ecron Acunova Limited, buy the company report.

Board of directors of Ecron Acunova Limited

Ecron Acunova has 3 current directors and 29 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Ranganathan PraveenAdditional Director15 Oct 20242 Years 1 MonthsCurrent
Priya Jebarani AldamAdditional Director15 Oct 20242 Years 1 MonthsCurrent
Raghavendra ShettyAdditional Director20 Nov 20251 Years 0 MonthsCurrent

Peer comparison

Ecron Acunova Limited is compared with the 3 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
QPS Bioserve India Private Limited₹78.02 Cr (FY 2025)11.0%Hyderabad, Telangana, India
Difgen Pharmaceuticals Private Limited₹76.63 Cr (FY 2025)84.0%Hyderabad, Telangana, India
Ecron Acunova Limitedthis company₹75.29 Cr (FY 2025)₹16.19 Cr21.5%20.0%123Bangalore, Karnataka, India
RCC Laboratories India Private Limited₹68.9 Cr (FY 2025)31.0%Telangana, India

To see the full peer comparison of Ecron Acunova Limited, buy the company report.

Shareholding

The shareholding of Ecron Acunova Limited is on record for 5 financial years, the latest being FY 2025, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2025FY 2024FY 2023FY 2022FY 2021
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Ecron Acunova Limited, buy the company report.

Charges & borrowings

Open charges
₹102.69 Cr
Satisfied charges
₹147.21 Cr
Breakdown by lending institutions
Others₹102.69 Cr
State Bank of India₹44.52 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
22 Dec 2017100151156Others₹102.69 CrSatisfied
28 Jun 201310438703State Bank of India₹20 LakhSatisfied
27 Jul 200590193026State Bank of India₹44.32 CrSatisfied

To see the full charge records of Ecron Acunova Limited, buy the company report.

Total charge records: 3 View all charges

Deals & funding

Ecron Acunova Limited has 22 deals on record (12 funding rounds, 10 secondary share transfers), with disclosed funding of ₹79.04 Cr; the latest was in August 2016.

Total deals
22
Funding rounds
12
Secondary share transfers
10
Disclosed funding
₹79.04 Cr

Deals on record (5 of 22)

WhenDealAmountParties
Sep 2010Secondary share transferUndisclosedBuyer: Acunova Life Sciences Private Limited , Manipal Education And Medical Group India Private Limited, 2 individuals
Seller: IL&FS Investment Managers, 2 individuals
Feb 2010Funding round₹4.17 CrInvestors: Acunova Life Sciences Private Limited , an individual
Sep 2008Secondary share transferUndisclosedBuyer: Manipal Education And Medical Group India Private Limited, 3 individuals
Seller: Memg International India Private Limited , 3 individuals
Apr 2008Funding round₹60 LakhInvestors: Acunova Life Sciences Private Limited
Jan 2008Funding round₹4.04 CrInvestors: Acunova Life Sciences Private Limited , 3 individuals

To see the full deal history of Ecron Acunova Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Ecron Acunova Limited was last rated by Care on 06 Sep 2023.

Rating agencyRated onRating
Care06 Sep 2023

To see the full credit ratings and regulatory alerts of Ecron Acunova Limited, buy the company report.

MSME payment delays

Ecron Acunova Limited has 9 MSME Form 1 returns on record between 2019 and 2023, listing 665 overdue payments to 31 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 31)

SupplierAmount dueDue sinceReported on
Ultra International
MDC Healthcare Private Limited
Hta Instrumentation Private Limited
Radiant Specialty Diagnostics
an individual supplier

To see the full MSME payment records of Ecron Acunova Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Ecron Acunova Limited has a workforce of 123 employees on its EPFO records as of May 2026, across 1 active EPFO establishment.

Employee count
123
Active EPFO establishments
1
Employee growth
-6.8%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-27123
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17

To see the full employee and EPFO history of Ecron Acunova Limited, buy the company report.

GST

Ecron Acunova has 3 GST registrations: 2 active and 1 cancelled or inactive.

Total GSTINs
3
Active
2
Cancelled / inactive
1
GSTINStateStatusRegistered on
29AAECM1039J2ZDKarnatakaActive01 Jul 2017
33AAECM1039J1ZPTamil NaduActive31 Oct 2017

To see the full GST registrations and return filing status of Ecron Acunova Limited, buy the company report.

Recent activity

Ecron Acunova Limited has 27 board changes on record since 2009: 4 appointments and 23 cessations. The latest: Raghavendra Shetty was appointed as Additional Director on 20 Nov 2025.

Appointed
Raghavendra Shetty was appointed as Additional Director.
AGM
Ecron Acunova Limited last Annual general meeting of members was held on 30 Sep 2025 as per latest MCA records.
Charges
A charge registered on 22 Dec 2017 via Charge ID 100151156 with Others was fully satisfied on 01 Jul 2025.
Filing
Ecron Acunova Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore.
Ceased
Vedamirtham Venkatesan ceased to be CFO.
Appointed
Priya Jebarani Aldam was appointed as Additional Director.
Appointed
Ranganathan Praveen was appointed as Additional Director.
Ceased
Pattabhiraman Srinivasan ceased to be Company Secretary.
Ceased
Ramesh Gopal ceased to be Additional Director.
Charges
A charge with Others of Rs. 102.69 Cr registered on 22 Dec 2017 with Charge ID 100151156 was modified on 28 Oct 2020.
Ceased
Chella Gowrishankar ceased to be Additional Director.
Ceased
Subhaskrishna Hebri Ballal ceased to be Director.

26 earlier events are in the company report.

Frequently asked questions

Ecron Acunova is an active public limited company based in Bangalore, Karnataka, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 17 December 2004 (22+ years old) and is registered under CIN U73100KA2004PLC035260.

Ecron Acunova has 3 current directors:

The latest financial statements of Ecron Acunova on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Ecron Acunova is 29AAECM1039J2ZD, registered in Karnataka. The company has 3 GST registrations in all, of which 2 are active and 1 is cancelled or inactive. Other active GSTINs include 33AAECM1039J1ZP (Tamil Nadu).

The CIN (Corporate Identification Number) of Ecron Acunova is U73100KA2004PLC035260. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Ecron Acunova has 9 court cases on record: 3 filed by the company and 6 filed against it. 3 are pending. Most are in the high courts.

Ecron Acunova was incorporated on 17 December 2004, making it 22+ years old. It is registered with the Registrar of Companies, Bangalore.

Ecron Acunova has 22 deals on record (12 funding rounds, 10 secondary share transfers), with disclosed funding of ₹79.04 Cr; the latest was in August 2016.

The peers of Ecron Acunova by revenue are QPS Bioserve India Private Limited, Difgen Pharmaceuticals Private Limited, RCC Laboratories India Private Limited, all in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development).

Raghavendra Shetty was appointed as Additional Director on 20 Nov 2025. Vedamirtham Venkatesan ceased to be CFO on 05 Nov 2024. Priya Jebarani Aldam was appointed as Additional Director on 15 Oct 2024. Ecron Acunova has 27 board changes on record in total.

Ecron Acunova has 9 MSME Form 1 returns on record between 2019 and 2023, listing 665 overdue payments to 31 micro and small suppliers. The latest return was filed on 29 Aug 2023.

Ecron Acunova can be reached through the website navitaslifesciences.com. Its registered office is in Bangalore, Karnataka, India.